Cargando…

Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals

Chikungunya fever is a mosquito-transmitted infectious disease that induces rash, myalgia, and persistent incapacitating arthralgia. At present, no vaccines or antiviral therapies specific to Chikungunya virus (CHIKV) infection have been approved, and research is currently restricted to biosafety le...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hui-Chung, Chiao, Der-Jiang, Shu, Pei-Yun, Lin, Hui-Tsu, Hsiung, Chia-Chu, Lin, Chang-Chi, Kuo, Szu-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101068/
https://www.ncbi.nlm.nih.gov/pubmed/36856407
http://dx.doi.org/10.1128/spectrum.04854-22
_version_ 1785025427199229952
author Lin, Hui-Chung
Chiao, Der-Jiang
Shu, Pei-Yun
Lin, Hui-Tsu
Hsiung, Chia-Chu
Lin, Chang-Chi
Kuo, Szu-Cheng
author_facet Lin, Hui-Chung
Chiao, Der-Jiang
Shu, Pei-Yun
Lin, Hui-Tsu
Hsiung, Chia-Chu
Lin, Chang-Chi
Kuo, Szu-Cheng
author_sort Lin, Hui-Chung
collection PubMed
description Chikungunya fever is a mosquito-transmitted infectious disease that induces rash, myalgia, and persistent incapacitating arthralgia. At present, no vaccines or antiviral therapies specific to Chikungunya virus (CHIKV) infection have been approved, and research is currently restricted to biosafety level 3 containment. CHIKV-like replicon particles (VRPs) are single-cycle infectious particles containing viral structure proteins, as well as a defective genome to provide a safe surrogate for living CHIKV to facilitate the testing of vaccines and antivirals. However, inefficient RNA transfection and the potential emergence of the competent virus through recombination in mammalian cells limit VRP usability. This study describes a transfection-free system for the safe packaging of CHIK VRP with all necessary components via transduction of mosquito cell lines using a single baculovirus vector. We observed the release of substantial quantities of mosquito cell-derived CHIK VRP (mos-CHIK VRP) from baculovirus-transduced mosquito cell lines. The VRPs were shown to recapitulate viral replication and subgenomic dual reporter expression (enhanced green fluorescent protein [eGFP] and luciferase) in infected host cells. Interestingly, the rapid expression kinetics of the VRP-expressing luciferase reporter (6 h) makes it possible to use mos-CHIK VRPs for the rapid quantification of VRP infection. Treatment with antivirals (suramin or 6-azauridine) or neutralizing antibodies (monoclonal antibodies [MAbs] or patient sera) was shown to inhibit mos-CHIK VRP infection in a dose-dependent manner. Ease of manufacture, safety, scalability, and high throughput make mos-CHIK VRPs a highly valuable vehicle for the study of CHIKV biology, the detection of neutralizing (NT) antibody activity, and the screening of antivirals against CHIKV. IMPORTANCE This study proposes a transfection-free system that enables the safe packaging of CHIK VRPs with all necessary components via baculovirus transduction. Those mosquito cell-derived CHIK VRP (mos-CHIK VRPs) were shown to recapitulate viral replication and subgenomic dual reporter (enhanced green fluorescent protein [eGFP] and luciferase) expression in infected host cells. Rapid expression kinetics of the VRP-expressing luciferase reporter (within hours) opens the door to using mos-CHIK VRPs for the rapid quantification of neutralizing antibody and antiviral activity against CHIKV. To the best of our knowledge, this is the first study to report a mosquito cell-derived alphavirus VRP system. Note that this system could also be applied to other arboviruses to model the earliest event in arboviral infection in vertebrates.
format Online
Article
Text
id pubmed-10101068
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-101010682023-04-14 Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals Lin, Hui-Chung Chiao, Der-Jiang Shu, Pei-Yun Lin, Hui-Tsu Hsiung, Chia-Chu Lin, Chang-Chi Kuo, Szu-Cheng Microbiol Spectr Research Article Chikungunya fever is a mosquito-transmitted infectious disease that induces rash, myalgia, and persistent incapacitating arthralgia. At present, no vaccines or antiviral therapies specific to Chikungunya virus (CHIKV) infection have been approved, and research is currently restricted to biosafety level 3 containment. CHIKV-like replicon particles (VRPs) are single-cycle infectious particles containing viral structure proteins, as well as a defective genome to provide a safe surrogate for living CHIKV to facilitate the testing of vaccines and antivirals. However, inefficient RNA transfection and the potential emergence of the competent virus through recombination in mammalian cells limit VRP usability. This study describes a transfection-free system for the safe packaging of CHIK VRP with all necessary components via transduction of mosquito cell lines using a single baculovirus vector. We observed the release of substantial quantities of mosquito cell-derived CHIK VRP (mos-CHIK VRP) from baculovirus-transduced mosquito cell lines. The VRPs were shown to recapitulate viral replication and subgenomic dual reporter expression (enhanced green fluorescent protein [eGFP] and luciferase) in infected host cells. Interestingly, the rapid expression kinetics of the VRP-expressing luciferase reporter (6 h) makes it possible to use mos-CHIK VRPs for the rapid quantification of VRP infection. Treatment with antivirals (suramin or 6-azauridine) or neutralizing antibodies (monoclonal antibodies [MAbs] or patient sera) was shown to inhibit mos-CHIK VRP infection in a dose-dependent manner. Ease of manufacture, safety, scalability, and high throughput make mos-CHIK VRPs a highly valuable vehicle for the study of CHIKV biology, the detection of neutralizing (NT) antibody activity, and the screening of antivirals against CHIKV. IMPORTANCE This study proposes a transfection-free system that enables the safe packaging of CHIK VRPs with all necessary components via baculovirus transduction. Those mosquito cell-derived CHIK VRP (mos-CHIK VRPs) were shown to recapitulate viral replication and subgenomic dual reporter (enhanced green fluorescent protein [eGFP] and luciferase) expression in infected host cells. Rapid expression kinetics of the VRP-expressing luciferase reporter (within hours) opens the door to using mos-CHIK VRPs for the rapid quantification of neutralizing antibody and antiviral activity against CHIKV. To the best of our knowledge, this is the first study to report a mosquito cell-derived alphavirus VRP system. Note that this system could also be applied to other arboviruses to model the earliest event in arboviral infection in vertebrates. American Society for Microbiology 2023-03-01 /pmc/articles/PMC10101068/ /pubmed/36856407 http://dx.doi.org/10.1128/spectrum.04854-22 Text en Copyright © 2023 Lin et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Lin, Hui-Chung
Chiao, Der-Jiang
Shu, Pei-Yun
Lin, Hui-Tsu
Hsiung, Chia-Chu
Lin, Chang-Chi
Kuo, Szu-Cheng
Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals
title Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals
title_full Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals
title_fullStr Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals
title_full_unstemmed Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals
title_short Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals
title_sort development of a novel chikungunya virus-like replicon particle for rapid quantification and screening of neutralizing antibodies and antivirals
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101068/
https://www.ncbi.nlm.nih.gov/pubmed/36856407
http://dx.doi.org/10.1128/spectrum.04854-22
work_keys_str_mv AT linhuichung developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals
AT chiaoderjiang developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals
AT shupeiyun developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals
AT linhuitsu developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals
AT hsiungchiachu developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals
AT linchangchi developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals
AT kuoszucheng developmentofanovelchikungunyaviruslikerepliconparticleforrapidquantificationandscreeningofneutralizingantibodiesandantivirals